Skip to content
<title>Channels - Cost-utility of first-line dostarlimab plus carboplatin-paclitaxel compared with placebo for patients with pA/rEC: a partitioned survival analysis :: FRELIP Discovery
Channels Cost-utility of first-line dostarlimab plus carboplatin-paclitaxel compared with placebo for patients with pA/rEC: a partitioned survival analysis
BRICS Plus: de-dollarization and global power shifts in new economic landscape
Hedging Grain Price Risk through Insurance-plus-Futures: The Case of China's Corn Industry
Probing the exchange rate’s asymmetric reaction to oil price changes in the new BRICS Plus group
EC50 and EC95 of remifentanil to prevent rocuronium-induced withdrawal movements in children
Ground fault location analysis on transmission lines using MATLAB/Simulink environment
R&D impact in the changes of economic structure of population
Product-Line Diversification and Financial Performance: The Case of the Macedonian Non-Life Insurance Market
R&D tax credits, innovative activity and the targeting approach
NAVIGATING BUSINESS CHANGE IN OTTOMAN İZMİR: A QUANTITATIVE ANALYSIS OF FIRM SURVIVAL (1888-1893)
A taxonomy for data-driven business models by Hanafizadeh, P., & Ashhari, R.
The Technological Bridge: R Programming’s Utility in Converting Social Media Data for Quantitative Financial Analysis
Sharing Debt and Houses: Strategies for Surviving Late Capitalism Among Aging Ghanaian Migrants in Canada
LCPP: Learning Curve Plus Plus
Cost-effectiveness of zanubrutinib versus ibrutinib in the first-line treatment for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China
Sustainable relationship between FDI, R&D, and CO2 emissions in emerging markets: An empirical analysis of BRICS countries
The lactate (pa)redox of memory
RecStitchNet: Learning to stitch images with rectangular boundaries
The Role of Open Innovation Ecosystems in the Internationalization of Born Global Firms: A Resource-based Perspective by TanTai, B., Isa, R.M., Senik, Z.C., & Muhamad, N.S.
Multi‐employer collective bargaining in liberal market economies: Reasons for survival and reinvigoration
STLLM-Rec: enhancing explainable recommendation via self-training LLMs
RecSys-Fairness: A Framework for Reducing Group Unfairness in Recommendations
Clinical outcomes with first-line tislelizumab plus lenvatinib in unresectable hepatocellular carcinoma: a retrospective analysis
EC-Bench: a benchmark for enzyme commission number prediction
Retraction: Synergistic Antitumor Effects of Novel HDAC Inhibitors and Paclitaxel In Vitro and In Vivo
